Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

May 25, 2023

Study Completion Date

June 26, 2023

Conditions
Cutaneous Lupus Erythematosus
Interventions
DRUG

SAR443122

Pharmaceutical form: Capsule Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Capsule Route of administration: Oral

Trial Locations (50)

1085

Investigational Site Number : 3480001, Budapest

3002

Investigational Site Number : 0360002, East Melbourne

3124

Investigational Site Number : 0360001, Camberwell

6720

Investigational Site Number : 3480002, Szeged

16132

Investigational Site Number : 3800001, Genova

20122

Investigational Site Number : 3800002, Milan

28046

Investigational Site Number : 7240004, Madrid

28211

DJL Clinical Research, PLLC Site Number : 8400003, Charlotte

31000

Investigational Site Number : 4840004, Chihuahua City

33024

GNP Research Site Number : 8400008, Cooper City

43213

ClinOhio Research Services Site Number : 8400007, Columbus

53002

Investigational Site Number : 2030006, Pardubice

64460

Investigational Site Number : 4840001, Monterrey, Nuevo León

65691

Investigational Site Number : 2030002, Brno

76018

Investigational Site Number : 8040001, Ivano-Frankivsk

77054

Prolato Clinical Research Center Site Number : 8400010, Houston

91910

Investigational Site Number : 4840002, Veracruz

115419

Investigational Site Number : 6430005, Moscow

125993

Investigational Site Number : 6430002, Moscow

160015

Investigational Site Number : 3560002, Chandigarh

197022

Investigational Site Number : 6430001, Saint Petersburg

350020

Investigational Site Number : 6430004, Krasnodar

355020

Investigational Site Number : 6430003, Stavropol

422101

Investigational Site Number : 3560004, Nashik

440019

Investigational Site Number : 3560003, Nagpur

5110683

Investigational Site Number : 1520009, Valdivia

5311523

Investigational Site Number : 1520006, Osorno

7500010

Investigational Site Number : 1520007, Santiago

7580206

Investigational Site Number : 1520003, Santiago

7640881

Investigational Site Number : 1520001, Santiago

8420383

Investigational Site Number : 1520002, Santiago

C1023AAB

Investigational Site Number : 0320002, CABA

C1055AAO

Investigational Site Number : 0320003, CABA

C1111

Investigational Site Number : 0320001, CABA

S2000DBS

Investigational Site Number : 0320004, Rosario

M5500

Investigational Site Number : 0320005, Mendoza

N6A2C2

Investigational Site Number : 1240001, London

M4W 2W4

Investigational Site Number : 1240005, Toronto

J1L 0H8

Investigational Site Number : 1240002, Sherbrooke

547 01

Investigational Site Number : 2030004, Náchod

160 00

Investigational Site Number : 2030005, Prague

03100

Investigational Site Number : 4840003, Benito Juárez

30-033

Investigational Site Number : 6160006, Krakow

20-081

Investigational Site Number : 6160004, Lublin

40-611

Investigational Site Number : 6160007, Katowice

08035

Investigational Site Number : 7240002, Barcelona

08041

Investigational Site Number : 7240007, Barcelona

08907

Investigational Site Number : 7240001, L'Hospitalet de Llobregat

04209

Investigational Site Number : 8040002, Kyiv

E11 1NR

Investigational Site Number : 8260003, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY